Evidence map›Paper›PMID 23606723›Full record

ReviewJournal of immunology (Baltimore, Md. : 1950)2013

Innate immunity and its regulation by mast cells.

Ashley L St John, Soman N Abraham

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05007522 (Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Proof-of-Concept Clinical Trial to Evaluate the Efficacy of Ketotifen and Indomethacin for Mild and Moderate COVID-19 in Adults), which is not on this map. Cited by 106 papers.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05007522 phase3completednot on this mapstarted 2022, after this paper: background citation

Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Proof-of-Concept Clinical Trial to Evaluate the Efficacy of Ketotifen and Indomethacin for Mild and Moderate COVID-19 in Adults

TypeinterventionalSponsorSen-Jam PharmaceuticalRan2022 to 2024Enrolled150ConditionsCOVID-19 Respiratory InfectionArmsKetotifen/Indomethacin, Placebo
3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 216 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Deciphering the Role of Mast Cells in HPV-Related Cancers.International journal of molecular sciences · 2025
    Review
  6. Review
  7. Review
  8. Seborrheic Dermatitis: Exploring the Complex Interplay withInternational journal of molecular sciences · 2025
    Review
  9. Biogenesis and homeostasis of mast cell lysosome related secretory granules.Frontiers in cell and developmental biology · 2025
    Review
  10. Article
  11. Review
  12. Antidepressant-like Effects ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  13. Review
  14. Article
  15. Infection of endemic chubParasitology · 2024
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Ashley L St JohnProgram in Emerging Infectious Diseases, Duke-National University of Singapore, Singapore. ashley.st.john@duke-nus.edu.sg
Soman N Abraham
Duke University Hospital · USNational Centre for Infectious Diseases · SG

Funding

Development of Efficacious and Stable Nasal Vaccine FormulationsU01AI082107 · NIAID · DUKE UNIVERSITY · PI STAATS, HERMAN F · 2009 to 2013
$3.8M
LIGAND RECEPTOR INTERACTIONS IN UTISR37DK050814 · NIDDK · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N · 1999 to 2008
$2.7M
Overcoming Immunosenescence by Nanoparticle-Mediated ActivationR01AI096305 · NIAID · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N, LEONG, KAM W · 2012 to 2016
$1.8M
Modulation of Bladder cAMP to combat UTI'sR01DK077159 · NIDDK · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N · 2007 to 2011
$1.7M
Mast Cells in Dengue Pathology and PreventionR01HL112921 · NHLBI · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N · 2013 to 2016
$1.5M
Immune mediated exocytosis of intravesicular UPEC from bladder cellsR01DK101456 · NIDDK · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N · 2014 to 2017
$1.4M
Development of Efficacious Vaccine Against UTI'sR21DK077307 · NIDDK · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N · 2008 to 2010
$529k
Nasal adjuvant to enhance anti-cocaine vaccinesR21DA029731 · NIDA · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N, STAATS, HERMAN F · 2011 to 2012
$432k
Mechanism of Bacterial Expulsion from Infected Bladder Cells.R56DK095198 · NIDDK · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N · 2012 to 2012
$200k
NHLBI NIH HHS R01 HL112921NIAID NIH HHS R01 AI096305NIAID NIH HHS R01-AI096305NIAID NIH HHS U01 AI082107NIAID NIH HHS U01-AI082107NIDA NIH HHS R21 DA029731NIDDK NIH HHS R01 DK077159NIDDK NIH HHS R01 DK101456NIDDK NIH HHS R21 DK077307NIDDK NIH HHS R37 DK050814NIDDK NIH HHS R56 DK095198NIDDK NIH HHS R56-DK095198
6 · The paper itself

Abstract

Mast cells (MCs), which are granulated tissue-resident cells of hematopoietic lineage, constitute a major sensory arm of the innate immune system. In this review we discuss the evidence supporting the dual role of MCs, both as sentinels for invading pathogens and as regulatory cells throughout the course of acute inflammation, from its initiation to resolution. This versatility is dependent on the ability of MCs to detect pathogens and danger signals and release a unique panel of mediators to promote pathogen-specific clearance mechanisms, such as through cellular recruitment or vascular permeability. It is increasingly understood that MCs also contribute to the regulated contraction of immune activation that occurs within tissues as inflammation resolves. This overarching regulatory control over innate immune processes has made MCs successful targets to purposefully enhance or, alternatively, suppress MC responses in multiple therapeutic contexts.

Indexed as

AnimalsHumansImmunity, InnateInflammationMast Cells

Identifiers

PMID23606723
PMCPMC3645001
OpenAlexW1893318402

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.